Prostate Cancer - Results from #19080

#GU15 - Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience - Session Highlights February 28, 2015

#GU15 - Correlation of baseline serum testosterone and PSA at 7 months in patients with new metastatic prostate cancer treated with continuous ADT - Session Highlights February 27, 2015

#GU15 - Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets - Session Highlights February 27, 2015

#GU15 - AR modulation optimized for response in splice variant (ARMPR3-SV): A RCT of galeterone vs enzalutamide in men expressing ARv7 in mCRPC - Session Highlights February 27, 2015

#GU15 - Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel - Session Highlights February 27, 2015

#GU15 - Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone - Session Highlights February 27, 2015

#GU15 - The impact of time to metastasis on survival in treatment-naïve prostate cancer patients - Session Highlights February 27, 2015

A multidisciplinary clinic to mitigate the impact of androgen deprivation therapy in prostate cancer: A pilot study - Session Highlights February 27, 2015

#GU15 - Best of journals: mCRPC treatment - Session Highlights February 27, 2015

A dose-response analysis of biochemical control outcomes after (125)i monotherapy for patients with favorable-risk prostate cancer - Abstract February 27, 2015

Periprostatic fat thickness on MRI: Correlation with Gleason score in prostate cancer - Abstract February 27, 2015

Surface-enhanced Raman spectroscopy + support vector machine: A new noninvasive method for prostate cancer screening? - Abstract February 27, 2015

Laparascopic radical prostatectomy - Abstract February 27, 2015

Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: A multi-institutional outcome study of 266 patients - Abstract February 27, 2015

#GU15 - Best of journals: Prostate cancer - Session Highlights February 27, 2015

#GU15 - Best of journals - Session Highlights February 27, 2015

#GU15 - Dynamic changes in biomarkers for immune response to sipuleucel-T for mCRPC - Session Highlights February 27, 2015

#GU15 - FANCA loss as a biomarker of platinum sensitivity in prostate cancer - Session Highlights February 27, 2015

#GU15 - Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014 - Session Highlights February 27, 2015

#GU15 - Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)? - Session Highlights February 27, 2015

Page 955 of 1457